investorscraft@gmail.com

Stock Analysis & ValuationCrescent Biopharma, Inc. (CBIO)

Previous Close
$12.07
Sector Valuation Confidence Level
High
Valuation methodValue, $Upside, %
Artificial intelligence (AI)n/an/a
Intrinsic value (DCF)n/a
Graham-Dodd Methodn/a
Graham Formulan/a

Company Information

300 Fifth Avenue
Waltham, MA 02451
United States
Phone: 617-430-5595
Industry: Biotechnology
Sector: Healthcare
CEO: Joshua T. Brumm
Full Time Employees: 41

Crescent Biopharma, Inc., a biotechnology company, researches and develops cancer therapy candidates. Its pipeline includes CR-001, a proprietary anti-PD-1/anti-VEGF bispecific antibody to treat solid tumors; and CR-002, and CR-003. The company has a strategic partnership with Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. for the development and commercialization of oncology therapeutics, including novel combinations. The company is headquartered in Waltham, Massachusetts.

HomeMenuAccount